Persistent Asset Partners Ltd Takes $543,000 Position in Dianthus Therapeutics, Inc. $DNTH

Persistent Asset Partners Ltd acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to its most recent filing with the SEC. The fund acquired 5,571 shares of the company’s stock, valued at approximately $543,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new position in Dianthus Therapeutics in the 2nd quarter worth about $93,000. SCS Capital Management LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $914,000. Bank of New York Mellon Corp bought a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $24,993,000. State of Wyoming bought a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $300,000. Finally, Walleye Capital LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth about $1,743,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Adam M. Veness sold 16,167 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the sale, the senior vice president directly owned 3,833 shares of the company’s stock, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 284,306 shares of company stock valued at $29,289,369 over the last three months. Corporate insiders own 3.02% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of analyst reports. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, HC Wainwright raised their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $115.96 on Monday. The stock’s 50-day simple moving average is $97.47 and its two-hundred day simple moving average is $83.07. Dianthus Therapeutics, Inc. has a twelve month low of $19.84 and a twelve month high of $116.47. The firm has a market capitalization of $6.34 billion, a P/E ratio of -27.94 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.